(713) 799-9975

Clinical Trials



YOSEMITE GR40349 – Genentech - Roche 

A Phase III, Multicenter, Randomized, Double-Masked, active comparator controlled study to evaluate the efficacy and safety of RO6867461 in patients with diabetic macular edema.


TENAYA  GR40306 – Genentech - Roche

A Phase III, Multicenter, Randomized, Double-Masked, active comparator controlled study to evaluate the efficacy and safety of FARICIMAB in patients with neovascular age related macular degeneration.


RAVEN – CRTH258C2302  Novartis

An Eighteen-Month, Two-Arm, Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Central Retinal Vein Occlusion.



 HAWK - RTH258-C001   Alcon Research Ltd.

Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration 2015-2018


CEDAR/SEQUIOA - AGN150998-005/006 - Allergan

Safety and Efficacy of Abicipar Pegol in Patients with Neovascular Age-related Macular Degeneration- 2016-2019


AERPIO - Trialrunners AKB - 9778 CI 5001 

Phase 2 Double-masked, Placebo-controlled Study To Assess The Safety And Efficacy Of Subcutaneously Administered AKB 9778 15mg Once Daily Or 15mg Twice Daily For 12 Months In Patients With Moderate To Severe Non-Proliferative Diabetic Retinopathy - 2017-2019


SCORE2 - NIH (National Eye Institute)     2014 – 2016

 Study of Comparative Treatments for Retinal Vein Occlusion 2 [SCORE2]: a multicenter, prospective, randomized non-inferiority trial of eyes with macular edema secondary to central retinal vein occlusion, comparing intravitreal bevacizumab every 4 weeks with intravitreal aflibercept every 4 weeks. 2014-2016



  • Diabetic Retinopathy in HIV Subjects Treated with EGRIFTA
  • Treatment for center-involved DME in Eyes with Very Good Visual Acuity
  • Short-term Evaluation of Combination Corticosteroid + Anti-VEGF Treatment for Persistent Central-involved Diabetic Macular Edema Following Anti-VEGF Therapy in Pseudophakic Eyes
  • Lucentis – Avastin Trial Design
  • Protocol “L”: Evaluation of Visual Acuity Measurements in Eyes with Diabetic Macular Edema
  • Protocol “N”: An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage due to Proliferative Diabetic Retinopathy
  • Mild Macular Grid (MMG) for Diabetic Macular Edema
  • Steroid Injection for Diabetic Macular Edema
  • Vitrectomy for Diabetic Macular Edema
  • Peribulbar Triamcinolone
  • PRP for Diabetic Macular Edema
  • Subclinical Diabetic Macular Edema
  • Anecortave Acetate for Wet AMD
  • Anecortave Acetate for Dry AMD
  • Surgical Therapeutics for Epiretinal Membranes and Vitrectomy
  • Branch Vein Occlusion Sheathotomy Study
  • Vit 100 (VitrenAse) Study for PVR
  • Oral treatment of Diabetic Retinopathy (Lilly)
  • Photodynamic Therapy (PDT) Study – Approved by FDA 4/2000
  • Macular Translocation for CNV
  • Perfluoron (PFO) Phase IV Clinical Trial
  • Submacular Surgery Pilot Trials (SST)
  • Perfluoron Study (PFO)
  • Syntex Ganciclovir Implant Trials
  • ISIS CMV Retinitis Trials
  • RPE Transplantation Study
  • Collaborative Ocular Melanoma
  • COMS
  • Macular Photocoagulation Study (MPS)
  • IOP Vitrectomy Study
  • Age-Related Eye Disease Study
  • Richard-James Silicone Oil Study
  • Vitrectomy for Macular Hole Study
  • Endophthalmitis Vitrectomy Study (EVS)
  • Advanced ROP Study